Drug Profile
IMM 201
Alternative Names: DAR 901; Heat-killed Mycobacterium vaccae strain NCTC 11659; IMM-201; SRL 172Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Silence Therapeutics
- Developer Aeras; Geisel School of Medicine; Immodulon Therapeutics; Tokyo Medical and Dental University; University of Colorado at Boulder
- Class Adjuvants; Antineoplastics; Antivirals; Tuberculosis vaccines
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Tuberculosis
- No development reported Post-traumatic stress disorders
- Discontinued Asthma; Atopic dermatitis; Hepatitis B; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Seasonal allergic rhinitis; Small cell lung cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA (Injection)
- 08 Apr 2021 IMM 201 is still in phase II trials for Mycobacterium tuberculosis in Tanzania (NCT02712424)
- 01 Feb 2020 Dartmouth-Hitchcock Medical Center at the Geisel School of Medicine completes a phase II DAR-PIA trial in Mycobacterium tuberculosis in Tanzania (NCT02712424)